Business Context and Reporting Period
This Form 8-K is filed by Sunshine Heart, Inc. (not Nuwellis, Inc.) on May 21, 2015. The report covers the results of the Company's annual meeting of stockholders held on that date and an update regarding the COUNTER HF clinical study.
Key Financial Metrics
This filing is a current report regarding corporate governance and clinical trial updates. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Corporate Actions
- Director Elections: Stockholders elected two Class II director nominees, David A. Rosa and Jon W. Salveson, to serve three-year terms.
- Accounting Firm Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2015.
- Clinical Study Update: On May 26, 2015, the Company announced FDA approval to resume enrollment in the COUNTER HF study, a pivotal trial evaluating the C-Pulse system for heart failure treatment.
Voting Results
| Proposal | Outcome | Key Vote Counts |
|---|---|---|
| Election of Directors (Class II) | Passed |
David A. Rosa: 3,122,963 For / 172,763 Withheld Jon W. Salveson: 3,129,439 For / 166,287 Withheld |
| Ratification of Auditors | Passed | 14,524,539 For / 15,826 Against / 61,124 Abstain |
Outlook, Risks, and Unusual Items
The filing highlights a significant operational milestone: the resumption of enrollment in the COUNTER HF study following FDA approval. This study assesses the safety and efficacy of the C-Pulse system for NYHA Class III and ambulatory Class IV heart failure. No specific financial guidance or new risk factors were disclosed in this text.
Investor Verification Checklist
- Verify the identity of the registrant as Sunshine Heart, Inc. (the input metadata incorrectly referenced Nuwellis, Inc.).
- Review the attached press release (Exhibit 99.1) for detailed implications of the FDA approval on the COUNTER HF study timeline.
- Confirm the composition of the Board of Directors following the election of the Class II nominees.
- Check subsequent filings for financial performance data, as this 8-K contains no financial statements.